The failure in a key pipeline candidate suggests potential challenges in Insmed's development strategy. Traders should assess the impact on overall pipeline value and watch for any management commentary on reallocation of resources to other programs. Consider this setback in context of the company's $35.4B market cap and recent insider selling activity.
INSM drugs
INSM drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 8 $160.18entry
- T+1 · 7mo ago −0.37%α −0.94% · $159.59
- T+5 · 7mo ago −8.39%α −11.91% · $146.74
- T+20 · 7mo ago −12.95%α −21.49% · $139.44
- T+60 · 4mo ago −30.33%α −40.79% · $111.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed announced that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) failed to meet primary or secondary efficacy endpoints, with both treatment arms showing inferior results to placebo. The company will discontinue development of brensocatib for HS, representing a significant setback for this pipeline candidate.
Key Facts
- Phase 2b CEDAR study failed to meet primary or secondary efficacy endpoints for brensocatib in hidradenitis suppurativa
- At Week 16, brensocatib 10 mg and 40 mg arms showed 45.5% and 40.3% reduction in abscess and inflammatory nodule count, respectively, compared to 57.1% reduction in placebo arm
- Insmed will discontinue development of brensocatib for HS indication
- Safety profile was consistent with previous studies with no new safety signals identified
Financial Impact
Elimination of potential future revenue from brensocatib in HS, with immediate R&D cost savings from discontinued program
Risk Factors
- Reputational damage to Insmed's clinical development capabilities
- Potential questions about the viability of other pipeline candidates
- Downward pressure on stock price due to failed clinical trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-013659 |
| Document: ef20070042_ex99-1.htm | 0001140361-26-013659 |
| Document: 0001140361-26-013659-index-headers.html | 0001140361-26-013659 |
| Document: 0001140361-26-013659-index.html | 0001140361-26-013659 |
| Document: 0001140361-26-013659.txt | 0001140361-26-013659 |
Track record
24 reports on INSM
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers